Remove Hot-Topics Mergers-and-Acquisitions
article thumbnail

Looking back at 2022: The top healthcare stories

Pharmaceutical Technology

Along the way, mergers and acquisitions continued to happen, new drugs and devices got approved, and innovations in the clinical trial industry were introduced. Along the way, mergers and acquisitions continued to happen, new drugs and devices got approved, and innovations in the clinical trial industry were introduced.

article thumbnail

Informa Connect’s Compliance Congress for Specialty Products

Drug Channels

Exclusive Offer – View the full agenda and register today. Use promo code SPECIALTY10 to save 10% off* your registration fee. Informa Connect will see you there! Cannot be combined with other offers, promotions or applied to an existing registration. Other restrictions may apply. Drug Channels, or any of its employees.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Kaia Health gets $75m for digital solution to strains and pains of pandemic workplace

pharmaphorum

Kaia Health has just announced a $75 million funding round for its technology, aimed at improving musculoskeletal (MSK) and chronic obstructive pulmonary disease (COPD) care. Founder and CEO Konstantin Mehl spoke to pharmaphorum’s news editor Richard Staines about why these treatments will be in demand as the world emerges from the pandemic.

article thumbnail

Why the New Xtalks Life Science Podcast is Essential Listening for Industry Professionals

XTalks

To complement its leading webinar, editorial and video content, the podcast will explore the latest news and hot topics in the pharmaceutical, biotechnology and medical device spaces. Fresh Conversations About Life Science Topics. Xtalks is proud to announce the launch of the Xtalks Life Science podcast.

article thumbnail

Clive Dix: Rebuilding UK biotech

pharmaphorum

But Dix has also been leading the UK’s Vaccine Taskforce, after taking over the hot seat in December following the departure of Kate Bingham. Before that he headed research and was a board member at PowderJect Pharmaceuticals until an acquisition by Chiron Vaccines in 2003.